These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10715309)

  • 1. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.
    Siena S; Schiavo R; Pedrazzoli P; Carlo-Stella C
    J Clin Oncol; 2000 Mar; 18(6):1360-77. PubMed ID: 10715309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
    Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
    Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC).
    Vogel W; Scheding S; Kanz L; Brugger W
    Stem Cells; 2000; 18(2):87-92. PubMed ID: 10742380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
    Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
    Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
    Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
    Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies.
    Brown RA; Adkins D; Goodnough LT; Haug JS; Todd G; Wehde M; Hendricks D; Ehlenbeck C; Laub L; DiPersio J
    J Clin Oncol; 1997 Sep; 15(9):3067-74. PubMed ID: 9294469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
    Watanabe T; Kawano Y; Watanabe A; Takaue Y
    Haematologica; 1999 Feb; 84(2):167-76. PubMed ID: 10091416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
    Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
    Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
    Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
    Andrews RG; Briddell RA; Hill R; Gough M; McNiece IK
    Stem Cells; 1999; 17(4):210-8. PubMed ID: 10437984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.
    Schwella N; Beyer J; Schwaner I; Heuft HG; Rick O; Huhn D; Serke S; Siegert W
    J Clin Oncol; 1996 Apr; 14(4):1114-21. PubMed ID: 8648365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
    Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
    Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
    Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
    J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.